GLI1
MOLECULAR TARGETGLI-Kruppel family member GLI1
GLI1 (GLI-Kruppel family member GLI1) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting GLI1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Anisomycin | 1.61 | 4 |
| 2 | Cladribine | 1.61 | 4 |
| 3 | clofilium tosylate | 1.61 | 4 |
| 4 | dihydrorotenone | 1.61 | 4 |
| 5 | Vorinostat | 1.39 | 3 |
| 6 | Calcimycin | 0.69 | 1 |
| 7 | cycloheximide | 0.69 | 1 |
| 8 | Niclosamide | 0.69 | 1 |
| 9 | streptonigrin | 0.69 | 1 |
| 10 | tyrphostin 9 | 0.69 | 1 |
About GLI1 as a Drug Target
GLI1 (GLI-Kruppel family member GLI1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented GLI1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
GLI1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.